reports
TTAM Research Institute, A Nonprofit Public Benefit Corporation, Compl...
TTAM Research Institute, A Nonprofit Public Benefit Corporation, Completes The Acquisition of 23andMe Assets SAN FRANCISCO, July 14, 2025 (GLOBE NEWSWIRE) -- TTAM Research Institute (“TTAM”), a nonprofit public benefit corporation based in California and founded and led by Anne Wojcicki, today announced that it has completed the acquisition of the Personal Genome Service (PGS) and Research Services business lines of 23andMe Holding Co. (together with its debtor subsidiaries, the “Company”) (OTC: MEHCQ), a genetics-led consumer healthcare company, under Section 363 of the U.S. Bankruptcy C...
23andMe Receives Court Approval for Sale to TTAM Research Institute, a...
23andMe Receives Court Approval for Sale to TTAM Research Institute, a Nonprofit Public Benefit Corporation SAN FRANCISCO, June 30, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a genetics-led consumer healthcare company, today announced that it has received approval from the U.S. Bankruptcy Court for the Eastern District of Missouri (the “Court") for the sale of substantially all of the Company's assets and ongoing business operations to TTAM Research Institute (“TTAM”), a nonprofit public benefit corporation based in California and led by 23andM...
- Pierre FerraguÊ
The Tech Infrastructure Quarterly Bible 1Q25
We publish today our comprehensive quarterly bible: 237 pages of detailed analyses on what happened in the last 3 months, and how we interpret it, in light of our current convictions. The first section acts as a PM summary, outlining our key findings, and latest thoughts on the semi cycle, in 6 slides.
ERIC B TELEFONAKTIEBOLAGET LM ERICSSON CLASS B
TSLA TESLA INC
PANW PALO ALTO NETWORKS INC.
NVDA NVIDIA CORPORATION
LRCX LAM RESEARCH CORPORATION
NOKIA NOKIA OYJ
2330 TSMC
SOI SOITEC SA
CSCO CISCO SYSTEMS INC.
ASML ASML HOLDING NV
MBLY MOBILEYE NV
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
AVGO BROADCOM INC.
TXG 10X GENOMICS INC CLASS A
ERIC-B ERICSSON LM-B SHS
0084207D UBER TECHNOLOGIES INC
ME 23ANDME HLDG CO
GRAB GRAB HLDGS LTD
ARM ARM HOLDINGS PLC
23andMe Reaches Agreement for Sale of Business to TTAM Research Instit...
23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process TTAM Commits to Comply with Company’s Privacy Policy and All Applicable Laws TTAM Commits to Adopting Additional Consumer Protections and Privacy Safeguards to Enhance Protections for Customer Data and Privacy No Changes to 23andMe’s Privacy Policy or Consumer Genome Services Transaction Subject to Court Approval SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a leading human genetics ...
23andMe Announces Intent to Voluntarily Delist from Nasdaq and Deregis...
23andMe Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC SAN FRANCISCO, May 27, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a leading human genetics and biotechnology company, today announced its intention to file a Form 25 Notification of Delisting with the Securities and Exchange Commission (the “SEC”) on or about June 6, 2025, which will remove its securities from listing and registration on Nasdaq. Nasdaq previously suspended the trading of 23andMe’s Class A common stock, $0.0001 par value per share (the “Common...
Regeneron, A Leading U.S. Biotechnology Company, to Acquire 23andMe in...
Regeneron, A Leading U.S. Biotechnology Company, to Acquire 23andMe in Court-Supervised Sale Regeneron Commits to Comply with Company’s Privacy Policy and All Applicable Law; No Changes to 23andMe’s Privacy Policy or Consumer Genome Services Transaction Subject to Court Approval SAN FRANCISCO, May 19, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a leading human genetics and biotechnology company, today announced that it has entered into a definitive agreement for the sale of 23andMe to Regeneron Pharmaceuticals, Inc. (“Regeneron”) (NASDAQ: RE...
23andMe Provides Update Regarding Court-Supervised Sale Process
23andMe Provides Update Regarding Court-Supervised Sale Process SAN FRANCISCO, April 18, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a leading human genetics and biotechnology company, today provided additional information on the protections in place for customer data in connection with the court-supervised sale of the Company’s assets. The process is being led by the Special Committee of the Company’s Board of Directors, which will evaluate potential acquisition bids, and supervised by the U.S. Bankruptcy Court for the Eastern District of Misso...
23andMe Confirms All Potential Buyers Must Agree to Comply With Privac...
23andMe Confirms All Potential Buyers Must Agree to Comply With Privacy Policy and Applicable Law Receives Court Approval for First Day Motions to Support Ongoing Business Operations SAN FRANCISCO, March 26, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (Nasdaq: ME), a leading human genetics and biotechnology company, today announced that it has received approvals from the U.S. Bankruptcy Court for the Eastern District of Missouri (the “Court”) for its “first day” motions related to 23andMe’s voluntary Chapter 11 petitions filed March 23, 2025, including auth...
- Pierre FerraguÊ
The Tech Infrastructure Quarterly Bible 4Q24
We publish today our comprehensive quarterly bible: 240 pages of detailed analyses on what happened in the last 3 months, and how we interpret it, in light of our current convictions. The first section acts as a PM summary, outlining our key findings, and latest thoughts on the semi cycle, in 6 slides.
PANW PALO ALTO NETWORKS INC.
NVDA NVIDIA CORPORATION
LRCX LAM RESEARCH CORPORATION
NOKIA NOKIA OYJ
2330 TSMC
SOI SOITEC SA
CSCO CISCO SYSTEMS INC.
ASML ASML HOLDING NV
MBLY MOBILEYE NV
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
AVGO BROADCOM INC.
IFX INFINEON TECHNOLOGIES AG
TXG 10X GENOMICS INC CLASS A
ERIC.B ERICSSON
ERIC-B ERICSSON LM-B SHS
0084207D UBER TECHNOLOGIES INC
ME 23ANDME HLDG CO
WOLF WOLFSPEED INC
GRAB GRAB HLDGS LTD
ARM ARM HOLDINGS PLC
23andMe Initiates Voluntary Chapter 11 Process to Maximize Stakeholder...
23andMe Initiates Voluntary Chapter 11 Process to Maximize Stakeholder Value Through Court-Supervised Sale Process Intends to use Proceedings to Conduct a Value-Maximizing Sale Process and Resolve Liabilities Company Expects to Continue Business Operations in the Ordinary Course During Proceedings; Secures Commitment for Approximately $35 Million in DIP Financing to Support Ongoing Operations No Changes to Customer Data Management and Access; Company Remains Committed to Transparency Around Customer Data Privacy; Any Buyer will be Required to Comply with Applicable Law with Respect to Tre...
23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and A...
23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab Test Provides 23andMe+ Premium members with highly requested insight into their likelihood of developing slightly elevated homocysteine levels SAN FRANCISCO, March 21, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company with a mission to help people access, understand, and benefit from the human genome, today released a new report on the genetics of homocysteine levels for 23andMe+ Premium members, as well as a blood test for next steps in further understanding s...
23andMe Special Committee Rejects Acquisition Proposal From CEO Anne W...
23andMe Special Committee Rejects Acquisition Proposal From CEO Anne Wojcicki SUNNYVALE, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- The Special Committee of the Board of Directors of 23andMe Holding Co. (“23andMe” or the “Company”) (Nasdaq: ME) today confirmed receipt of a non-binding proposal from Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, to acquire all of the outstanding shares of capital stock of 23andMe not owned by Ms. Wojcicki and her affiliates (or any other stockholders that she invites to “roll over” their current equity o...
23andMe Launches New Genetic Report on Osteoporosis
23andMe Launches New Genetic Report on Osteoporosis Provides 23andMe+ Premium members with insight into their likelihood of developing osteoporosis based on thousands of genetic variants SUNNYVALE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company with a mission to help people access, understand, and benefit from the human genome, today released a new polygenic risk score (PRS) report* on the genetics of osteoporosis for 23andMe+ Premium members. The report informs customers if they are at a higher likelihood of developing osteo...
23andMe Special Committee Announces Exploration of Strategic Alternati...
23andMe Special Committee Announces Exploration of Strategic Alternatives SUNNYVALE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- The Special Committee of the Board of Directors of 23andMe Holding Co. (Nasdaq: ME) (“23andMe” or the “Company”), a leading human genetics company with a mission to help people access, understand, and benefit from the human genome, today announced that it has undertaken a process to explore strategic alternatives, including, among other alternatives, a possible sale of the company, business combination, sale of all or part of the Company’s assets, licensing of ass...
23andMe Reports Third Quarter Fiscal Year 2025 Financial Results
23andMe Reports Third Quarter Fiscal Year 2025 Financial Results Company Notes Continued Concerns Regarding Liquidity and Consideration of Potential Ways to Address Operational and Financial Challenges SUNNYVALE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe,” the “Company,” “we,” “us,” and “our”), a leading human genetics company with a mission to help people access, understand, and benefit from the human genome, reported its financial results for the third quarter (“Q3”) of fiscal year 2025 (“FY25”), which ended December 31, 2024. Notable Items i...
23andMe Launches Discover23 to Help Accelerate Large-Scale Genetics Re...
23andMe Launches Discover23 to Help Accelerate Large-Scale Genetics Research For Biopharma Collaborators, Powered By Lifebit’s Trusted Technology 23andMe is helping collaborators better understand disease biology, identify novel targets, boost clinical trial success, and engage people in their care SUNNYVALE, Calif. and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company, today announced the launch of Discover23®, a new research offering enabling authorized collaborators to securely access the power and diversity of the 23andMe re...
23andMe and Mirador Therapeutics Enter Into Strategic Research Collabo...
23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador’s Precision Medicines for Immunology & Inflammation SUNNYVALE, Calif. and SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and preventive health company, and Mirador Therapeutics, a next-generation precision medicine company focused on developing first-in-class or best-in-class therapeutics for immunology and inflammation (I&I)-related diseases, today announced a strategic research collaboration. Under the agreement, Mirador will leverage a...
23andMe Reports Second Quarter Fiscal Year 2025 Financial Results
23andMe Reports Second Quarter Fiscal Year 2025 Financial Results SUNNYVALE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and preventive health company, reported its financial results for the second quarter of fiscal year 2025 (FY25), which ended September 30, 2024. Key Results: Improved GAAP Net Loss by 21% and Adjusted EBITDA by 26% for the same period in the prior year (see important additional information below).The 23andMe comprehensive Total Health longevity service is now available to all customers, combining wh...
23andMe Announces Business Restructuring to Streamline Operations, Red...
23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future Reduces workforce by roughly 40%; expects annualized cost savings of more than $35 million Discontinues development of therapeutics division and commences strategic alternatives process for all in-house therapeutic programs SUNNYVALE, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), a leading human genetics and preventive health company, today announced a business restructuring to streamline operations and reduce cost...
CORRECTION - 23andMe to Report Q2 FY2025 Financial Results
CORRECTION - 23andMe to Report Q2 FY2025 Financial Results SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- An earlier release under the same headline should have noted 23andMe Holding Co. (Nasdaq: ME) (23andMe) will report financial results for the second quarter of fiscal year 2025 (FY2025) prior to the market opening on Tuesday, November 12, 2024 (the prior release incorrectly stated the results would be reported after the market closes). The Company will webcast a conference call at 8:00 a.m. Eastern Time on that date to discuss the quarter’s results and report on business progres...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.